Atara Biotherapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application $(BLA.SI)$ for their innovative therapy, tabelecleucel (tab-cel®), with a Priority Review status. This application pertains to the use of tab-cel as a monotherapy for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) in both adult and pediatric patients who have undergone at least one prior therapy. Notably, there are currently no FDA-approved therapies available for this condition. The Priority Review includes a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date set for January 10, 2026. This development marks a significant step towards introducing this first-of-its-kind treatment to patients in the U.S.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.